ANI Pharmaceuticals Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- Wall Street ends higher as Amazon soothes AI jitters
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
ANI Pharma (ANIP) Misses Q3 EPS by 20c, Revenues Miss; Offers FY19 EPS/Revenue Guidance Below Consensus
November 6, 2019 8:32 AM ESTANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.23, $0.20 worse than the analyst estimate of $1.43. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.97 million.
For the third quarter 2019:
Net revenues of $51.3 million, an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32Adjusted non-GAAP EBITDA of $19.8 million and... More